HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%

MT Newswires Live

2024-11-22

HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.

The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.

After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.

CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.

The company's shares were down by 3% in recent trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485284990"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485284990\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485284990?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485284990","market":"fut","top_or_hot":-1,"title":"HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.</p><p>The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.</p><p>After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.</p><p>CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.</p><p>The company's shares were down by 3% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-22 15:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p> HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.</p><p>The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.</p><p>After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.</p><p>CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.</p><p>The company's shares were down by 3% in recent trading.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485284990","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485284990","pubTimestamp":1732260110,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED   FRUZAQLA , its metastatic colorectal cancer  drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA became the first oral targeted therapy for metastatic colorectal cancer  in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","BK1191":"制药","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","BK4213":"石油与天然气的勘探与生产","00013":"和黄医药","BK1587":"次新股","CRC":"加州资源"},"translate_title":"和黄医药（中国）将与武田在日本推出口服结直肠癌药物；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"CRC":1},"content_text":"HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1}}}